Zymeworks director awarded options and RSUs

Q: What insider transactions did Zymeworks (ZYME) report on this Form 4?

The Form 4 shows that director Gregory Austin Ciongoli received 11,500 stock options at an exercise price of $23.16 and 7,700 RSUs on January 12, 2026.

Q: When do Gregory Austin Ciongoli’s Zymeworks stock options and RSUs vest?

The filing states that the 11,500 stock options vest on January 12, 2027, and the 7,700 restricted stock units also vest on January 12, 2027.

Q: How many Zymeworks stock options does the director hold after this transaction?

After the reported grant, the director beneficially owns 11,500 stock options for Zymeworks common stock, held as direct ownership.

Q: How many Zymeworks RSUs does the director hold after this Form 4 filing?

Following the grant reported, the director holds 7,700 restricted stock units for Zymeworks common stock, reported as directly owned.

Q: Did the Zymeworks director sell any shares in this Form 4?

No sales are reported. The transactions are coded as "A" (acquired) for both the 11,500 stock options and 7,700 RSUs, indicating equity awards granted rather than shares sold.

Q: What does each Zymeworks RSU represent in this insider filing?

Each restricted stock unit represents the right to receive one share of common stock upon vesting, as described in the footnotes to the Form 4.

Zymeworks Inc. director Gregory Austin Ciongoli reported new equity awards on a Form 4.

Accepted by SEC EDGAR 01/12/2026 - 08:59 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zymeworks Inc. director Gregory Austin Ciongoli reported new equity awards on a Form 4. On January 12, 2026, he was granted stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036.

He also received 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and these RSUs vest on January 12, 2027. All reported derivative holdings are shown as directly owned, and the filing reflects awards being acquired rather than any sale of shares.

Insider Trade Summary

Grant/Award: 19,200 shares

Grant/Award 2 txns

Insider Ciongoli Gregory Austin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	11,500	$0.00	$0.00
Grant/Award	Restricted Stock Unit	7,700	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 11,500 contracts (Direct); Restricted Stock Unit — 7,700 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 11,500 contracts (Direct); Restricted Stock Unit, 0 to 7,700 contracts (Direct)

Footnotes (3)

F1. Stock options vest on January 12, 2027.
F2. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3. RSUs vest on January 12, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Zymeworks (ZYME) report on this Form 4?

The Form 4 shows that director Gregory Austin Ciongoli received 11,500 stock options at an exercise price of $23.16 and 7,700 RSUs on January 12, 2026.

When do Gregory Austin Ciongoli’s Zymeworks stock options and RSUs vest?

The filing states that the 11,500 stock options vest on January 12, 2027, and the 7,700 restricted stock units also vest on January 12, 2027.

How many Zymeworks stock options does the director hold after this transaction?

After the reported grant, the director beneficially owns 11,500 stock options for Zymeworks common stock, held as direct ownership.

How many Zymeworks RSUs does the director hold after this Form 4 filing?

Following the grant reported, the director holds 7,700 restricted stock units for Zymeworks common stock, reported as directly owned.

Did the Zymeworks director sell any shares in this Form 4?

No sales are reported. The transactions are coded as "A" (acquired) for both the 11,500 stock options and 7,700 RSUs, indicating equity awards granted rather than shares sold.

What does each Zymeworks RSU represent in this insider filing?

Each restricted stock unit represents the right to receive one share of common stock upon vesting, as described in the footnotes to the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciongoli Gregory Austin

(Last)

(First)

(Middle)

C/O ZYMEWORKS INC.

108 PATRIOT DRIVE, SUITE A

(Street)

MIDDLETOWN

19709

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$23.16	01/12/2026		A		11,500		01/12/2027⁽¹⁾	01/11/2036	Common Stock	11,500	$0.00	11,500	D
Restricted Stock Unit	⁽²⁾	01/12/2026		A		7,700		01/12/2027⁽³⁾	01/12/2027⁽³⁾	Common Stock	7,700	$0.00	7,700	D

Explanation of Responses:

1. Stock options vest on January 12, 2027.

2. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

3. RSUs vest on January 12, 2027.

	/s/ Daniel Dex, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR